← All trials
NCT06695910
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 6, 2024
- Primary completion
- Mar 10, 2026
- Completion date
- Jun 1, 2026
- First posted
- Nov 19, 2024
- Last posted
- Nov 22, 2024
- Enrollment
- 48
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SCF PharmaLead sponsor
- Institut de recherche clinique du littoral (IRCL)Collaborator
- SCF PharmaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.